Phase II at NCI now open for enrollment. | ZIOP Message Board Posts

ZIOPHARM Oncology, Inc.

  ZIOP website

ZIOP   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  110866 of 111522  at  9/21/2019 12:57:31 PM  by

Gottaluvdabus


Strong Buy

Phase II at NCI now open for enrollment.

 

A Phase II Study Using the Administration of Autologous T-cells Engineered using the Sleeping Beauty Transposon/Transposase System to Express T-Cell Receptors Reactive Against Mutated Neoantigens in Patients with Metastatic Cancer

The Ziopharm/NCI TCR-T cell trial at the NCI has been initiated. As of yesterday, the trial is in "Open - Not Yet Recruiting" status. Per the NCI posting, it will be a Phase II, see below. The trial has not been posted on clinicaltrials.gov yet as of this post. Excellent news.

A Phase II Study Using the Administration of Autologous T-cells Engineered using the Sleeping Beauty Transposon/Transposase System to Express T-Cell Receptors Reactive Against Mutated Neoantigens in Patients with Metastatic Cancer
Open - Not yet Recruiting Summary Not Yet Available. Call Referral Contact.
NCI PROTOCOL IDNCI-19-C-0143
INVESTIGATORSteven A. Rosenberg, M.D., Ph.D.
SHARE THIS TRIAL: REFERRAL CONTACTS
Immunotherapy Recruitment Center866-820-4505


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 27     Views: 581
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
110867 Re: Phase II at NCI now open for enrollment. biolurker1 0 9/21/2019 2:26:14 PM






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...